Volume 14 Supplement 4

New therapeutic targets in systemic lupus


Edited by Jennifer Anolik

The supplement was proposed and developed by the journal. Articles were commissioned by the journal, were independently prepared by the authors and have undergone the journal's standard peer review process. Publication of the supplement has been supported by an unrestricted educational grant from UCB. Completed articles underwent a data quality check by Darwin Healthcare Communications, funded by UCB.

  1. Review

    B-cell selection and the development of autoantibodies

    The clearest evidence that B cells play an important role in human autoimmunity is that immunotherapies that deplete B cells are very effective treatments for many autoimmune diseases. All people, healthy or i...

    Natalia V Giltiay, Craig P Chappell and Edward A Clark

    Arthritis Research & Therapy 2012 14(Suppl 4):S1

    Published on: 2 November 2012

  2. Review

    B-cell activating factor targeted therapy and lupus

    B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the survival and differentiation of B cells. The successful development of belimumab, a human antibody targeting soluble ...

    Alexis Boneparth and Anne Davidson

    Arthritis Research & Therapy 2012 14(Suppl 4):S2

    Published on: 2 November 2012

  3. Review

    Unmet medical needs in systemic lupus erythematosus

    Systemic lupus erythematosus (SLE) is an autoimmune disease of diverse manifestations, with onset usually in young women in the third to fourth decade of life. The chronic nature of this relapsing remitting di...

    Aisha Lateef and Michelle Petri

    Arthritis Research & Therapy 2012 14(Suppl 4):S4

    Published on: 18 December 2012